Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $14.00 price target on the stock. Chardan Capital's target price would suggest a potential upside of 93.91% from the stock's previous close.
Separately, HC Wainwright began coverage on Coya Therapeutics in a report on Monday, September 16th. They set a "buy" rating and a $18.00 price target for the company.
Get Our Latest Analysis on COYA
Coya Therapeutics Stock Down 0.6 %
Shares of COYA stock traded down $0.04 during trading hours on Thursday, reaching $7.22. 46,790 shares of the company's stock were exchanged, compared to its average volume of 71,665. Coya Therapeutics has a fifty-two week low of $4.40 and a fifty-two week high of $10.69. The business has a fifty day moving average price of $6.97 and a 200-day moving average price of $7.05.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.19) EPS for the quarter. The firm had revenue of $3.43 million during the quarter. On average, equities analysts predict that Coya Therapeutics will post -1.27 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Gilbert & Cook Inc. acquired a new position in shares of Coya Therapeutics in the second quarter valued at $61,000. Renaissance Technologies LLC acquired a new position in shares of Coya Therapeutics in the second quarter valued at $101,000. GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics in the third quarter valued at $169,000. Finally, Vanguard Group Inc. raised its stake in shares of Coya Therapeutics by 772.3% in the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company's stock valued at $8,407,000 after purchasing an additional 750,338 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.
Coya Therapeutics Company Profile
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
See Also
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
